Highlights:

  • DistributeRx launch drives prescription volumes significantly above expectations
  • Strong growth in Women’s Health portfolio led by BIJUVA® and NEXTSTELLIS®
  • Robust cash generation strengthens Balance Sheet and growth flexibility

Overview

Mayne Pharma Group Limited (ASX:MYX) reported steady performance in 3Q FY26, with Revenue rising 1% to $85.2 million and improved margins driven by pricing discipline and product mix. The quarter was marked by strong momentum in its Women’s Health segment and the successful launch of DistributeRx, which exceeded prescription Volume expectations. Despite seasonal headwinds linked to US insurance cycles, the company delivered a 90% increase in Operating Cash Flow. Backed by improved cash reserves and regulatory tailwinds, Mayne Pharma enters the final quarter with solid commercial traction and a focus on scaling its key growth platforms.

Is DistributeRx Transforming Mayne Pharma’s Growth Strategy?

The launch of DistributeRx represents a major strategic shift for Mayne Pharma Group Limited, aiming to streamline prescription distribution and improve patient access. Since its rollout, the platform has significantly outperformed internal forecasts, with prescription volumes exceeding expectations by over 70%. It has rapidly expanded its prescriber base and increased engagement with existing users. By integrating manufacturer, pharmacy, and customer services, DistributeRx is positioning itself as a scalable healthcare ecosystem, offering meaningful growth potential across dermatology and beyond.

How Is Women’s Health Driving Performance?

Mayne Pharma’s Women’s Health segment continues to be a key growth engine, supported by strong Demand for products like BIJUVA® and NEXTSTELLIS®. Prescription growth has been driven by enhanced Marketing strategies, improved healthcare provider engagement, and favourable regulatory developments, including updated labelling by the U.S. Food and Drug Administration. This update is expected to boost prescribing confidence. Despite temporary Supply constraints for BIJUVA®, the company remains focused on expanding its presence in the growing menopause treatment market and improving patient access through targeted investments.